<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01257776</url>
  </required_header>
  <id_info>
    <org_study_id>CeTMAd/ICPD/2008</org_study_id>
    <nct_id>NCT01257776</nct_id>
  </id_info>
  <brief_title>Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia in Diabetic Patients</brief_title>
  <official_title>Phase I-II Study of the Use of Human Adipose Derived Mesenchymal Stem Cells as Regenerative Therapy in Diabetic Patients With Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Progreso y Salud, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Progreso y Salud, Spain</source>
  <oversight_info>
    <authority>Spain: Spanish Medicine and Health-Care Products Agency. Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Critical limb ischaemia in diabetic patients is associated with high rates of morbidity and
      mortality. Sub-optimal responses to the available medical and surgical treatments are common
      in these patients, who also demonstrate limited vascular homeostasis. Neovasculogenesis
      induced by stem cell therapy could be a useful approach for these patients.

      This is a randomized, open, controlled and multicentric study aimed to assess the safety and
      efficacy of intra-arterial administration of autologous adipose derived mesenchymal stem
      cells, in diabetic patients with critical limb ischemia of at least one limb and absence of
      any revascularization option.

      36 patients would be included and randomized into four groups of 9 patients, depending on
      the mesenchymal stem cells concentration to be administered: 0,5 million cells/kg; 1 million
      cells/kg; 2 million cells/kg; and controlled group.

      Efficacy primary endpoint is the angiographic demonstration of neovasculogenesis at 6 months
      follow up.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Angiographic assessment of neovasculogenesis (angiogenesis plus arteriogenesis)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Target limb vascularization would be quantified by a dedicated software, MetaMorph® v.6.3, by using Angiogenesis Tube Formation application module. Neovasculogenesis would be the difference between vascularization at baseline and 6 months follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse event (death, target limb amputation)</measure>
    <time_frame>1 month, 6 months, 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ankle Brachial Index</measure>
    <time_frame>1 month, 6 months, 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>University of Texas Classification at target limb</measure>
    <time_frame>1 month, 6 months, 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cells 0,5 million * weight (kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group of low dose of Mesenchymal stem cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesenchymal stem cells 1 million * weight (kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group of mid dose of mesenchymal stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesenchymal stem cells 2 million * weight (kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group of high dose of mesenchymal stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controlled group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Controlled group with no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous adipose derived mesenchymal stem cells</intervention_name>
    <description>Intra-arterial administration through a selective cannulation of target common femoral artery</description>
    <arm_group_label>Mesenchymal stem cells 0,5 million * weight (kg)</arm_group_label>
    <arm_group_label>Mesenchymal stem cells 1 million * weight (kg)</arm_group_label>
    <arm_group_label>Mesenchymal stem cells 2 million * weight (kg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes, type 1 or 2

          -  Critical Limb Ischemia (Rutherford Becker Class II,III or IV)of at least one limb.

          -  No options for target limb revascularization.

        Exclusion Criteria:

          -  Cancer antecedent in the last two years

          -  Current limb infection or limb gangrene
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael J Ruiz-Salmeron, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Virgen Macarena. Seville.Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio De la Cuesta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Virgen Macarena. Seville.Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inmaculada C Perez-Camacho, MD, PhD</last_name>
    <phone>+34955693440</phone>
    <email>ipercam06@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rafael J Ruiz-Salmerón, MD, PhD</last_name>
    <phone>+34955693440</phone>
    <email>rjruizsalmeron@yahoo.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Virgen Macarena</name>
      <address>
        <city>Seville</city>
        <zip>41007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inmaculada C Perez-Camacho, MD,PhD</last_name>
      <phone>+34955693440</phone>
      <email>ipercam06@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Francisco Marcos, MD, Phd</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela De-Araujo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cesar Carrascosa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inmaculada C Perez-Camacho, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel A Rico, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CABIMER (Andalusian Center for Molecular Biology and Regenerative Medicine)</name>
      <address>
        <city>Seville</city>
        <zip>41092</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inmaculada C Perez-Castejon, MD, PhD</last_name>
      <phone>+34955693440</phone>
      <email>ipercam06@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Abdelkrim Hmadcha, MD, PhD</last_name>
      <phone>+34955693440</phone>
      <email>Karim.Hmadcha@cabimer.es</email>
    </contact_backup>
    <investigator>
      <last_name>Abdelkrim Hmadcha, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Itziar Ochotorena, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernat Soria, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natividad Cuende, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <lastchanged_date>December 9, 2010</lastchanged_date>
  <firstreceived_date>December 9, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Fundacion Progreso y Salud</name_title>
    <organization>Regional Andalusian Health Ministry</organization>
  </responsible_party>
  <keyword>Critical Limb Ischemia</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Regenerative Therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
</clinical_study>
